ASTELLAS PHARMA

The 'Meningitis - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of meningitis clinical trials, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, providing insights into global clinical trials landscape and enrollment trends.

Ionis Pharmaceuticals' Tryngolza is the first FDA-approved treatment for familial chylomicronemia syndrome (FCS). FDA senior advisor Robert Temple to retire. Zealand Pharma's glepaglutide for short bowel syndrome rejected, requiring an additional trial. Sangamo grants Astellas rights to use a viral capsid for gene therapy delivery. BioAge Labs partners with Novartis to discover drug targets for age-related illnesses.

Sangamo Therapeutics and Astellas Pharma entered a license agreement for Sangamo's neurotropic AAV capsid, STAC-BBB, granting Astellas exclusive rights for one target with options for four additional neurological disease targets. Sangamo will receive a $20 million upfront fee and could earn up to $1.3 billion in additional target fees and milestone payments, plus royalties on potential net sales. Astellas will manage all research, development, manufacturing, and commercialization activities.

Japan's biopharma industry, once a global leader, declined significantly post-1990s due to economic stagnation, reduced R&D investment, and regulatory hurdles. Recent government initiatives aim to revitalize the sector, including easing drug approval processes and supporting startups, signaling potential for an upswing.

The FDA added a Boxed Warning for rare but serious liver injury to fezolinetant (Veozah) labeling, an oral neurokinin 3 receptor antagonist for moderate to severe vasomotor symptoms due to menopause. This follows a postmarketing report of elevated liver blood test values and symptoms in a patient after 40 days of therapy, which resolved upon discontinuation. Increased liver blood testing frequency is now recommended.

FDA issued a black-box warning for Veozah, a hormone-free hot flash drug, due to rare but severe liver risks. Regular blood tests are recommended, and patients should stop the medication if experiencing liver injury symptoms.

The global Acute Myeloid Leukemia Therapeutics Market is projected to grow at a CAGR of 13.4% during 2024-2032, driven by advances in targeted therapies and immunotherapies.

Insomnia market report forecasts growth from 2020 to 2034, driven by increasing prevalence, awareness, and emerging therapies like Seltorexant and TS-142. Challenges include high treatment costs and patient non-compliance, with unmet needs for long-term solutions with minimal side effects.

The antibiotics and antimycotics market is projected to reach $91.54 billion by 2031, driven by infectious disease prevalence and R&D initiatives. Key players include Pfizer, Novartis, and Sanofi. North America leads in revenue, with APAC expected to show highest growth.

The 2025 Patients as Partners meeting focuses on patient-centric drug development, advocacy integration, and clinical trial efficiencies, featuring keynotes by Jayne Gershkowitz, Dr. Ify Osunkwo, Dr. Justin Hopkin, and Anthony Yanni. Topics include diversity, patient engagement measures, AI, digital tech, and regulatory updates.